Does CSF p-tau181 help to discriminate Alzheimer’s disease from other dementias and mild cognitive impairment? A meta-analysis of the literature

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Journal of neural transmission

• Publication date

  2014-05-10

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1007/s00702-014-1226-yPMID 24817210
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Addition of MHPG to Alzheimer's disease biomarkers improves differentiation of dementia with Lewy bodies from Alzheimer's disease but not other dementias

  2014cited by this paper
• Cerebrospinal fluid biomarkers of Alzheimer's disease in healthy elderly.

  2013cited by this paper
• CCL2 Is Associated with a Faster Rate of Cognitive Decline during Early Stages of Alzheimer's Disease

  2012influential reference
• P2‐006: Increased cerebrospinal fluid levels of double‐stranded RNA‐dependant protein kinase in Alzheimer's disease

  2012influential reference
• Neuropathologic substrates of Parkinson disease dementia

  2012cited by this paper
• Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease.

  2012cited by this paper
• Preclinical AD Workgroup staging: pathological correlates and potential challenges.

  2012cited by this paper
• Altered CSF Orexin and α-Synuclein Levels in Dementia Patients

  2012influential reference
• Biomarkers of dementia: comparison of electrochemiluminescence results and reference ranges with conventional ELISA.

  2012influential reference
• Longitudinal Changes of CSF Biomarkers in Alzheimer's Disease

  2011influential reference
• Alzheimer's disease.

  2011cited by this paper
• Value of Neuropsychological Tests, Neuroimaging, and Biomarkers for Diagnosing Alzheimer's Disease in Younger and Older Age Cohorts

  2011influential reference
• Tau and p-tau as CSF biomarkers in dementia: a meta-analysis

  2011cited by this paper
• Association between cerebrospinal fluid tau and brain atrophy is not related to clinical severity in the Alzheimer's disease continuum.

  2011influential reference
• Impact of SORL1 Single Nucleotide Polymorphisms on Alzheimer’s Disease Cerebrospinal Fluid Markers

  2011cited by this paper
• Decreased sAβPPβ, Aβ38, and Aβ40 Cerebrospinal Fluid Levels in Frontotemporal Dementia

  2011influential reference
• CSF amyloid β38 as a novel diagnostic marker for dementia with Lewy bodies

  2010influential reference
• Tau-Proteins as Gender-Specific State Markers in Amnestic Mild Cognitive Impairment

  2010cited by this paper
• Total and phosphorylated tau protein as biological markers of Alzheimer's disease.

  2010cited by this paper
• Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer's disease.

  2010cited by this paper
• Cerebrospinal fluid abnormalities and rate of decline in everyday function across the dementia spectrum: normal aging, mild cognitive impairment, and Alzheimer disease.

  2010influential reference
• The cerebrospinal fluid amyloid beta42/40 ratio in the differentiation of Alzheimer's disease from non-Alzheimer's dementia.

  2010influential reference
• Reduced sample sizes for atrophy outcomes in Alzheimer's disease trials: baseline adjustment.

  2010influential reference
• Alzheimer disease.

  2010influential reference
• Subtypes based on cerebrospinal fluid and magnetic resonance imaging markers in normal elderly predict cognitive decline.

  2010cited by this paper
• Brain perfusion SPECT correlates with CSF biomarkers in Alzheimer’s disease

  2010cited by this paper
• 3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects.

  2010cited by this paper
• Whole-brain atrophy rate and CSF biomarker levels in MCI and AD: a longitudinal study.

  2010cited by this paper
• Relations between brain tissue loss, CSF biomarkers, and the ApoE genetic profile: a longitudinal MRI study.

  2010cited by this paper
• Glycemia and Levels of Cerebrospinal Fluid Amyloid and Tau in Patients Attending a Memory Clinic

  2010cited by this paper
• Differential levels of α-synuclein, β-amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer's disease

  2010influential reference
• Additional Value of CSF Amyloid-β40 Levels in the Differentiation between FTLD and Control Subjects

  2010influential reference
• Cystatin C Levels are Positively Correlated with both Aβ42 and Tau Levels in Cerebrospinal Fluid in Persons with Alzheimer's Disease, Mild Cognitive Impairment, and Healthy Controls

  2010cited by this paper
• CSF alpha-synuclein levels in dementia with Lewy bodies and Alzheimer's disease.

  2009influential reference
• Atypical frontotemporal lobar degeneration with ubiquitin-positive, TDP-43-negative neuronal inclusions

  2009influential reference
• Conflict of Interest: None

  2009influential reference
• Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects

  2009cited by this paper
• Cerebrospinal Fluid Biomarkers and Prediction of Conversion in Patients with Mild Cognitive Impairment: 4-Year Follow-Up in a Routine Clinical Setting

  2009influential reference
• Diagnostic accuracy of Alzheimer’s disease: A clinicopathological study

  2009cited by this paper
• Formation and development of Lewy pathology: a critical update

  2009cited by this paper
• Relationships between biomarkers in aging and dementia

  2009cited by this paper
• CSF phosphorylated tau in the diagnosis and prognosis of mild cognitive impairment and Alzheimer’s disease: a meta-analysis of 51 studies

  2009cited by this paper
• Pattern of Tau forms in CSF is altered in progressive supranuclear palsy.

  2009cited by this paper
• Rapid Progression from Mild Cognitive Impairment to Alzheimer’s Disease in Subjects with Elevated Levels of Tau in Cerebrospinal Fluid and the APOE ε4/ε4 Genotype

  2009cited by this paper
• Baseline CSF p-tau levels independently predict progression of hippocampal atrophy in Alzheimer disease

  2009influential reference
• Tau forms in CSF as a reliable biomarker for progressive supranuclear palsy

  2008cited by this paper
• Prevalence and impact of vascular and Alzheimer pathologies in Lewy body disease

  2008cited by this paper
• Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies.

  2008influential reference
• Cerebrospinal Fluid Neurochemical Phenotypes in Vascular Dementias: Original Data and Mini-Review

  2008cited by this paper
• Cerebrospinal fluid levels of tau phosphorylated at threonine 181 in patients with Alzheimer’s disease and vascular dementia

  2008cited by this paper
• Intrathecal levels of IL-6, IL-11 and LIF in Alzheimer's disease and frontotemporal lobar degeneration

  2008cited by this paper
• P2‐188: Atypical frontotemporal lobar degeneration with ubiquitin‐positive, TDP‐43‐negative neuronal inclusions

  2008cited by this paper
• Diagnostic markers for diagnosing dementia with Lewy bodies: CSF and MIBG cardiac scintigraphy study.

  2007cited by this paper
• Longitudinal changes of CSF biomarkers in memory clinic patients

  2007cited by this paper
• Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline

  2007cited by this paper
• Clinical diagnostic criteria for dementia associated with Parkinson's disease

  2007influential reference
• LOW specificity limits the use of the cerebrospinal fluid AB1-42/P-TAU181P ratio to discriminate alzheimer's disease from vascular dementia.

  2007cited by this paper
• Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study.

  2006cited by this paper
• Total tau protein, phosphorylated tau (181p) protein, beta-amyloid(1-42), and beta-amyloid(1-40) in cerebrospinal fluid of patients with dementia with Lewy bodies.

  2006cited by this paper
• Cerebrospinal fluid amyloid beta42/phosphorylated tau ratio discriminates between Alzheimer's disease and vascular dementia.

  2006cited by this paper
• Diagnosing prodromal Alzheimer's disease: role of CSF biochemical markers.

  2006influential reference
• Neuropsychological and behavioural correlates of CSF biomarkers in dementia.

  2006cited by this paper
• Total tau protein, phosphorylated tau (181p) protein, β-amyloid1–42, and β-amyloid1–40 in cerebrospinal fluid of patients with dementia with Lewy bodies

  2006cited by this paper
• International quality control survey of neurochemical dementia diagnostics.

  2006cited by this paper
• Cerebrospinal fluid tau and beta-amyloid in Alzheimer patients, disease controls and an age-matched random sample.

  2006cited by this paper
• Alzheimer's disease

  2006cited by this paper
• Measurement of Thirteen Biological Markers in CSF of Patients with Alzheimer’s Disease and Other Dementias

  2005cited by this paper
• Diagnosis and management of dementia with Lewy bodies

  2005cited by this paper
• Cerebrospinal fluid tau, Aβ1–42 and inflammatory cytokines in patients with Alzheimer's disease and vascular dementia

  2005cited by this paper
• Epidemiology and risk factors of dementia

  2005cited by this paper
• Core biological marker candidates of Alzheimer’s disease – perspectives for diagnosis, prediction of outcome and reflection of biological activity

  2004cited by this paper
• Cerebrospinal fluid protein biomarkers for Alzheimer’s disease

  2004cited by this paper
• CSF markers for incipient Alzheimer's disease.

  2003cited by this paper
• Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease.

  2003cited by this paper
• Decreased CSF-beta-amyloid 42 in Alzheimer's disease and amyotrophic lateral sclerosis may reflect mismetabolism of beta-amyloid induced by disparate mechanisms.

  2002cited by this paper
• Decreased CSF-β-Amyloid 42 in Alzheimer’s Disease and Amyotrophic Lateral Sclerosis May Reflect Mismetabolism of β-Amyloid Induced by Disparate Mechanisms

  2002cited by this paper
• Both total and phosphorylated tau are increased in Alzheimer's disease

  2001cited by this paper
• Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria.

  1999cited by this paper
• Frontotemporal lobar degeneration

  1998cited by this paper
• Observations on the brains of demented old people. B.E. Tomlinson, G. Blessed and M. Roth, Journal of the Neurological Sciences (1970) 11, 205–242; (1968) 7, 331–356

  1997cited by this paper
• Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the consortium on DLB international workshop

  1996cited by this paper
• Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB)

  1996cited by this paper
• Low frequency of post‐lumbar puncture headache in demented patients

  1993cited by this paper
• Vascular dementia

  1993cited by this paper
• Severity of family distress of schizophrenia—fact or artifact?

  1993cited by this paper
• Criteria for the diagnosis of ischemic vascular dementia proposed by the State of California Alzheimer's Disease Diagnostic and Treatment Centers

  1992cited by this paper
• QUANTITATIVE METHODS IN PSYCHOLOGY A Power Primer

  1992cited by this paper
• Intellectual Impairment in Parkinson's Disease: Clinical, Pathologic, and Biochemical Correlates

  1988cited by this paper
• Clinical diagnosis of Alzheimer's disease

  1984cited by this paper
• Observations on the brains of demented old people.

  1968cited by this paper
• Cerebrospinal fluid.

  1965influential reference
• Brain perfusion.

  1960cited by this paper
• [Clinical diagnostic].

  1955cited by this paper
• For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group. Review Dementia Associated with Parkinson's Disease Panel 1. Risk Factors for Dementia in Patients with Pd

  year unknowncited by this paper

• Cerebrospinal Fluid Biomarkers and Cognition in Alzheimer Disease and Frontotemporal Dementia in a Memory Clinic Setting

  2025cites this paper
• sTREM2 in discordant CSF Aβ42 and p‐tau181

  2025cites this paper
• The Associations of Phosphorylated Tau 181 and Tau 231 Levels in Plasma and Cerebrospinal Fluid with Cognitive Function in Alzheimer’s Disease: A Systematic Review and Meta-Analysis

  2024cites this paper
• The Relationship of Cerebrospinal Fluid Biomarkers and Cognitive Performance in Frontotemporal Dementia

  2024cites this paper
• CSF α-Synuclein and Tau as Biomarkers for Dementia With Lewy Bodies

  2022cites this paper
• Cerebrospinal Fluid Biomarkers in Autopsy-Confirmed Alzheimer Disease and Frontotemporal Lobar Degeneration

  2022cites this paper
• Blood Biomarkers for the Diagnosis of Neurodegenerative Dementia: A Systematic Review

  2022cites this paper
• Биомаркеры сосудистой когнитивной дисфункции

  2021cites this paper
• Neurofilament Proteins as Biomarkers to Monitor Neurological Diseases and the Efficacy of Therapies

  2021cites this paper
• New insights and therapeutic opportunities for progranulin-deficient frontotemporal dementia.

  2021cites this paper
• Biomarkers of vascular cognitive impairment

  2021cites this paper
• Development of disease-modifying drugs for frontotemporal dementia spectrum disorders

  2020cites this paper
• Fluid and imaging biomarkers for Alzheimer's disease: Where we stand and where to head to.

  2018cites this paper
• Precision medicine of frontotemporal dementia: from genotype to phenotype.

  2018cites this paper
• CSF Aβ1-42, but not p-Tau181, differentiates aMCI from SCI.

  2018cites this paper
• Cerebrospinal fluid α‐synuclein contributes to the differential diagnosis of Alzheimer's disease

  2018cites this paper
• Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer’s disease core biomarkers in Lewy body disorders and Alzheimer’s dementia

  2017cites this paper
• Associations between [18F]AV1451 tau PET and CSF measures of tau pathology in a clinical sample

  2017cites this paper
• Phenotype of postural instability/gait difficulty in Parkinson disease: relevance to cognitive impairment and mechanism relating pathological proteins and neurotransmitters

  2017cites this paper
• Alpha-synuclein in cerebrospinal fluid

  2017cites this paper
• Clinical validity of cerebrospinal fluid Aβ42, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework.

  2017cites this paper
• Neurochemical biomarkers in the diagnosis of frontotemporal lobar degeneration: an update

  2016cites this paper
• Cerebrospinal Fluid Biomarkers for the Differential Diagnosis between Alzheimer’s Disease and Frontotemporal Lobar Degeneration: Systematic Review, HSROC Analysis, and Confounding Factors

  2016cites this paper
• CSF biomarkers in neurodegenerative and vascular dementias.

  2016cites this paper
• Advances in neuroimaging in frontotemporal dementia

  2016cites this paper
• Diagnostic Value of Cerebrospinal Fluid Biomarkers (Phospho-Tau181, total-Tau, Aβ42, and Aβ40) in Prodromal Stage of Alzheimer's Disease and Dementia with Lewy Bodies.

  2016cites this paper
• Likvorski biomarkeri YKL-40 i p-tau181 u ranoj dijagnostici Alzheimerove bolesti

  2016cites this paper
• Use of CSF α-synuclein in the differential diagnosis between Alzheimer's disease and other neurodegenerative disorders

  2015cites this paper
• Cerebrospinal fluid Aβ40 is similarly reduced in patients with Frontotemporal Lobar Degeneration and Alzheimer's Disease.

  2015cites this paper
• New Frontiers in Alzheimer's Disease Diagnosis

  2015cites this paper
• Genetics and Underlying Pathology of Dementia

  2015cites this paper
• Alzheimer's disease--Recent biomarker developments in relation to updated diagnostic criteria.

  2015cites this paper